Treatment of Neurodegenerative Disorders through the Blood-brain Barrier using Nanocarriers Mallapragada, Surya Poovaiah, Nitya Davoudi, Zahra Peng, Haisheng Schlichtmann, Benjamin Mallapragada, Surya Narasimhan, Balaji Narasimhan, Balaji Wang, Qun
dc.contributor.department Ames Laboratory
dc.contributor.department Neuroscience
dc.contributor.department Materials Science and Engineering
dc.contributor.department Chemical and Biological Engineering 2018-09-09T11:03:45.000 2020-06-30T01:09:47Z 2020-06-30T01:09:47Z Mon Jan 01 00:00:00 UTC 2018 2019-08-27 2018-08-27
dc.description.abstract <p>Neurodegenerative diseases refer to disorders of the central nervous system (CNS) that are caused by neuronal degradations, dysfunctions, or death. Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease (APHD) are regarded as the three major neurodegenerative diseases. There is a vast body of literature on the causes and treatments of these neurodegenerative diseases. However, the main obstacle in developing an effective treatment strategy is the permeability of the treatment components to the blood-brain barrier (BBB). Several strategies have been developed to improve this obstruction. For example, nanomaterials facilitate drug delivery to the BBB due to their size. They have been used widely in nanomedicine and as nanoprobes for diagnosis purposes among others in neuroscience. Nanomaterials in different forms, such as nanoparticles, nanoemulsions, solid lipid nanoparticles (SLN), and liposomes, have been used to treat the neurodegenerative diseases. This review will cover the basic concepts and applications of nanomaterials in the therapy of APHD.</p>
dc.description.comments <p>This is a manuscript of an article published as Poovaiah, Nitya, Zahra Davoudi, Haisheng Peng, Benjamin Schlichtmann, Surya K. Mallapragada, Balaji Narasimhan, and Qun Wang. "Treatment of Neurodegenerative Disorders through the Blood-brain Barrier using Nanocarriers." <em>Nanoscale</em> (2018). DOI: <a href="" target="_blank">10.1039/C8NR04073G</a>. Posted with permission.</p>
dc.format.mimetype application/pdf
dc.identifier archive/
dc.identifier.articleid 1342
dc.identifier.contextkey 12782376
dc.identifier.s3bucket isulib-bepress-aws-west
dc.identifier.submissionpath cbe_pubs/342
dc.language.iso en
dc.source.bitstream archive/|||Fri Jan 14 23:41:51 UTC 2022
dc.source.uri 10.1039/C8NR04073G
dc.subject.disciplines Biochemical and Biomolecular Engineering
dc.subject.disciplines Biology and Biomimetic Materials
dc.subject.disciplines Biomechanics and Biotransport
dc.subject.disciplines Biomedical Engineering and Bioengineering
dc.subject.disciplines Nanoscience and Nanotechnology
dc.subject.keywords Neurodegenerative diseases
dc.subject.keywords Blood-brain barrier
dc.subject.keywords Drug delivery
dc.subject.keywords Nanocarriers
dc.title Treatment of Neurodegenerative Disorders through the Blood-brain Barrier using Nanocarriers
dc.type article
dc.type.genre article
dspace.entity.type Publication
relation.isAuthorOfPublication cf742fe7-cf8d-4bf5-98bd-00b8a45db967
relation.isAuthorOfPublication 185bb428-638b-41cf-91ff-d997d87c3543
relation.isOrgUnitOfPublication 25913818-6714-4be5-89a6-f70c8facdf7e
relation.isOrgUnitOfPublication 69754788-3b0f-45f3-be4d-004c4d08715e
relation.isOrgUnitOfPublication bf9f7e3e-25bd-44d3-b49c-ed98372dee5e
relation.isOrgUnitOfPublication 86545861-382c-4c15-8c52-eb8e9afe6b75
Original bundle
Now showing 1 - 1 of 1
2.72 MB
Adobe Portable Document Format